



Oxurion Receives Transparency Notification from Atlas Special **Opportunities LLC**

Leuven, BELGIUM, Boston, MA, US - October 3, 2023 - 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation¹ it has received a transparency notification as follows:

Oxurion received a transparency notification on October 3, 2023, from Atlas Special Opportunities, LLC indicating that as of September 29, 2023, it held 75,425,104 shares of the then outstanding 2,667,771,604 shares, and therefore crossed under the threshold (3%) by virtue of the sale of voting securities. See Annex 1.

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forwardlooking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.


For further information please contact:

Oxurion NV
Tom Graney
Chief Executive Officer
Tel: +32 16 75 13 10
tom.graney@oxurion.com

Michael Dillen Chief Business Officer Tel: +32 16 75 13 10 michael.dillen@oxurion.com US Conway Communications Mary T. Conway mtconway@conwaycommsir.com

^{1.} Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

ANNEX 1



9) Denominator

2,667,771,604

Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction				
	# of voting rights	# of voting rights		% of voting rights		
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities	
Atlas Special Opportunities LLC	127,316,529	75,425,104	0	2.83%	0.00%	
TOTAL		75,425,104		2.83%		



Sign Envelope ID: AD4C57A0-0385-480A-95E5-4F9B85F99BA7

B) Equivalent financial instruments	After the transaction						
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement	
							+
	TOTAL						

The totals will be updated once you have clicked on <CALCULATE>

TOTAL (A & B)		# of voting rights	% of voting rights	
	CALCULATE	75,425,104	2.83%	

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Aflas Special Opportunities LLC is not a controlled entity.	
12) In case of proxy voting for only one GM	
Holder will cease to hold / will hold again voting rights as of	(DD/MM/YYYY)
13) Additional information	
On 27 September 2023, Allas Special Opportunities LLC held 82,365,225 shares (= 3.09%) in Oxurion NV. On 29 September 2023, Allas Special Opportunities LLC sold 6,940,121 shares result of which its shareholding decreased to 75,425,104 shares (= 2.83%).	in Oxurion NV, as a
Done at New York	
On 02/10/2023 (DD/MMYYYY)	
Name & capacity Patrick Vance, proxyholder Signature Patrick Vance, proxyholder	